ClinicalTrials.gg
RecruitingNCT06320288VERTEBRALUpdated Jan 12, 2026

Analysis of Trunk and Center of Mass Control Development During Gait in Children With Cerebral Palsy (VERTEBRAL)

An observational study in Children With Cerebral Palsy, sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est. Recruiting at 1 site in France. Open to participants aged 18 Months to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
270
Ages
18 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Cerebral Palsy with a site in France — 29 open to participants now, 30 under way, none of them phase 3. Cerebral Palsy · France.

Planned enrollment
5th of 32
270 · median 58
Started
2023
with 8 others
Observational
32 of 91
9 open now
Primary completion
2026-09
later than 5 of 29 live
Registered
66th of 91
by date
Lead sponsor
4 of 91
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est

Among the 91 studies in Cerebral Palsy with a site in France, this one is the 5th largest by planned enrollment of the 32 observational ones that give a count, is one of 9 that started in 2023, is one of 32 observational ones, reaches primary completion later than 5 of the 29 other live ones, and was the 66th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

29 of the 91 studies in Cerebral Palsy with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 18 Months to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Cerebral Palsy with a site in France, or all of them as a file.
02

Study summary

During the acquisition of posturokinetic abilities such as walking, postural control of the trunk is of paramount importance. Indeed, its development is strongly linked to the overall motor function of children. In cerebral palsy (CP), a term that refers to a set of motor disorders following a perinatal lesion, deficits in axial control are present from early childhood. These deficits are strongly correlated with the functional deficits observed in this population. In particular, during walking, deviations of the trunk (amplitudes, accelerations) are observed in the three planes of space. While recent literature increasingly questions the impact of trunk control deficit on the walking of children with CP, elements are still missing for a holistic understanding of the interaction between locomotor and postural disorders in children with CP. In particular, no study has focused on the deviations of trunk control and the center of mass (which is a global indicator of balance strategies) during the development and maturation of walking in children with CP. Therefore, the primary objective of this cross-sectional observational study will be to characterize the development of trunk control and center of mass during walking in children with CP.

03

Conditions studied

  • Children With Cerebral Palsy

Browse trials for

04

Who can participate

Ages eligible
18 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children with cerebral palsy presenting gait pattern disorders receive consultation and/or care (day or full hospitalization) at the Flavigny-sur-Moselle CMPRE.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children (\< 18 years) with cerebral palsy
  • GMFCS I to III
  • Independent walking with or without technical walking aids (walker, crutches, etc.)
  • Able to understand the instructions of various clinical assessments and functional explorations
  • Affiliated with a social security scheme

Exclusion criteria

Exclusion Criteria:

Children with cerebral palsy

  • Neuro-orthopaedic surgery of the lower limbs or trunk within the last 12 months
  • Botulinum toxin A injections within the last 6 months
  • Therapeutic intervention targeting trunk control last 6 months

Typically developing children

  • Surgery on lower limbs or trunk last 12 months
  • Neurological and/or orthopedic pathology that may influence gait
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with cerebral palsy

    All children will undergo : * A neuro-articular assessment * A gait analysis on a walking track and with three inertial units to analyze the behavior of their trunk and center of mass during walking. * Assessment of gross motor function * Static posturography * Functional assessment of the trunk * Functional assessment of balance

  • Children with typical development

    All children will undergo : * A neuro-articular assessment * A gait analysis on a walking track and with three inertial units to analyze the behavior of their trunk and center of mass during walking. * Static posturography * Functional assessment of the trunk * Functional assessment of balance

06

What researchers measure

Primary outcomes

  1. Trunk and center-of-mass accelerations and acceleration variability

    In addition to the zeno walking track, inertial computers will be used to record accelerations of the patient's trunk and center of mass as they walk. One will be attached to the sternum, the other to the lumbosacral hinge, using hypoallergenic double-sided tape. A third will be attached to the patient's shoe to synchronize the data from the treadmill and the inertial units. Acceleration variability is calculated in post-processing.

    Time frame: At the end of the one-day experimental

Secondary outcomes

  1. Gait Variability Index

    A composite score of gait variability based on spatio-temporal parameters, giving an index of gait regularity. The mean reference score is 100, and a score above 100 indicates that the patient is at least as stable as a patient from a healthy population.

    Time frame: At the beginning of the one-day experimental

  2. Trunk Control Measurement Scale score (TCMS)

    The TCMS scale assesses trunk control in the seated position in three dimensions. The maximum (and best) score is 58 points, of which 20 correspond to static balance, 28 to selective movement control and 10 to the ability to perform dynamic extension movements.

    Time frame: At the beginning of the one-day experimental

  3. Early Clinical Assessment of Balance score

    The Early Clinical Assessment of Balance is an evaluative measure used by clinicians to assess balance in the cerebral palsy population. Scoring is on a 0-100 scale where higher scores equate to better balance.

    Time frame: At the beginning of the one-day experimental

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.

Of 217 non-industry observational studies under Cerebral Palsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 36 months is above that.

Counting every sponsor, half of 221 studies reached it within 21 months; a quarter within 8 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Mar 20, 2024
StartActual
Sep 20, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2028
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06320288
Lead sponsor
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Sep 20, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jan 12, 2026

Study contacts

Jonathan Pierret, PhD
Contact
jonathan.pierret@ugecam.assurance-maladie.fr
+33 3 82 52 6761

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion